• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2016 Fiscal Year Final Research Report

Integrated analyses of GBM cell lines, in vivo xenograft models, and clinical samples to examine the glutamine metabolism in response to mTOR-targeted treatments

Research Project

  • PDF
Project/Area Number 26462181
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Neurosurgery
Research InstitutionKobe University

Principal Investigator

TANAKA KAZUHIRO  神戸大学, 医学研究科, 医学研究員 (70467661)

Project Period (FY) 2014-04-01 – 2017-03-31
Keywordsグルタミン代謝 / グルタミナーゼ / mTOR / グリオーマ
Outline of Final Research Achievements

The impact of mTOR inhibition on metabolic reprogramming in malignant glioma is incompletely understood. Here, by integrating metabolic and functional studies in glioblastoma multiforme (GBM) cell lines, in vivo models and clinical samples, we demonstrate that the compensatory upregulation of glutamine metabolism promotes resistance to mTOR kinase inhibitors. Metabolomic studies reveal elevated glutaminase (GLS) and glutamate levels following mTOR kinase inhibitor treatment, which is confirmed in a xenograft model. GLS is shown to promote GBM survival following mTOR inhibitor treatment. Genetic and pharmacologic studies demonstrate that combined inhibition of mTOR kinase and GLS cause massive synergistic tumor cell death and growth inhibition in vivo. These results highlight a critical role for compensatory glutamine metabolism in promoting mTOR inhibitor resistance, and suggest a rational combination therapy to suppress it.

Free Research Field

医歯薬学

URL: 

Published: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi